Soligenix, Inc. announced that it has appointed Richard Straube, MD, as its Senior Vice President and Chief Medical Officer. He has had a long and distinguished career of more than 35 years in both academia and industry, most notably with Centocor, Ohmeda Pharmaceuticals, INO Therapeutics, and Stealth Peptides, Inc. Dr. Straube will lead Soligenix's clinical research with primary responsibility for the execution and completion of its multiple clinical programs, including its Phase 2 study in oral mucositis and its Phase 2/3 study in pediatric Crohn's disease.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.735 USD | +0.18% | -26.36% | -77.63% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-77.63% | 2.7M | |
+16.49% | 122B | |
+19.69% | 115B | |
+21.22% | 26.64B | |
-23.60% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-18.52% | 15.49B | |
+63.44% | 14.83B | |
+2.21% | 13.67B |
- Stock Market
- Equities
- SNGX Stock
- News Soligenix, Inc.
- Soligenix Appoints Richard Straube, MD, as Senior Vice President and Chief Medical Officer